Table of Contents

company-logo

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.

BrightPath Biotherapeutics Dividend Announcement

• BrightPath Biotherapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on BrightPath Biotherapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

BrightPath Biotherapeutics Dividend History

BrightPath Biotherapeutics Dividend Yield

BrightPath Biotherapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing BrightPath Biotherapeutics stock? Use our calculator to estimate your expected dividend yield:

BrightPath Biotherapeutics Financial Ratios

P/E ratio-3.19
PEG ratio-1.97
P/B ratio5.71
ROE-139.98%
Payout ratio0.00%
Current ratio8.78
Quick ratio8.78
Cash Ratio7.52

BrightPath Biotherapeutics Dividend FAQ

Does BrightPath Biotherapeutics stock pay dividends?
BrightPath Biotherapeutics does not currently pay dividends to its shareholders.
Has BrightPath Biotherapeutics ever paid a dividend?
No, BrightPath Biotherapeutics has no a history of paying dividends to its shareholders. BrightPath Biotherapeutics is not known for its dividend payments.
Why doesn't BrightPath Biotherapeutics pay dividends?
There are several potential reasons why BrightPath Biotherapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will BrightPath Biotherapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While BrightPath Biotherapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is BrightPath Biotherapeutics a dividend aristocrat?
BrightPath Biotherapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is BrightPath Biotherapeutics a dividend king?
BrightPath Biotherapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is BrightPath Biotherapeutics a dividend stock?
No, BrightPath Biotherapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy BrightPath Biotherapeutics stocks?
To buy BrightPath Biotherapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy BrightPath Biotherapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.